Correlation Engine 2.0
Clear Search sequence regions

  • apoptosis (1)
  • CD 1 (4)
  • epithelium (2)
  • intestines (1)
  • mice (9)
  • nasopharynx (1)
  • necrosis (1)
  • rats (2)
  • reflux (2)
  • sodium (9)
  • strains (1)
  • swollen abdomen (1)
  • Sizes of these terms reflect their relevance to your search.

    The tolerability of single daily gavage doses of 0.5% or 2.0% (wt/vol) sodium lauryl sulfate (SLS) in 11- to 12-week-old male CD-1 mice was evaluated in a study of 3 months in duration. Live-phase, gross necropsy, and histopathologic parameters were evaluated. Mortality of 14% occurred in mice administered formulations containing SLS. Clinical observations in mice administered SLS included abnormal respiration (audible, irregular, and/or labored), swollen abdomen, rough haircoat, hunched appearance, and hypoactivity. Necropsy findings in mice administered SLS consisted of enlarged intestines containing abnormal contents with gas. There were no instances of mechanical gavage-related injury. Histologic evaluation of the respiratory tract revealed injury to the nasal passages and nasopharynx, including, but not limited to, inflammation, exudate, apoptosis/necrosis of epithelium, and atrophy of epithelium or olfactory nerves. Collectively, the data indicated that under the experimental conditions of our 3-month study in male CD-1 mice, once-daily gavage administration of vehicle formulations containing SLS at 0.5% or 2.0% resulted in nasal injury and 14% mortality supportive of gastroesophageal reflux. Sponsors utilizing formulations containing SLS in toxicity studies in CD-1 mice should exclude gastroesophageal reflux as a confounding factor in studies with morbidity or mortality associated with respiratory distress or evidence of aerophagia.


    Armando R Irizarry Rovira, Kim G Hilbish, Matthew Schroeder, Gary A Boorman, Kelly M Credille, Darryl Ballard, Jeff C Hanson, Andrea Niedenthal. Effects of 0.5% and 2.0% Sodium Lauryl Sulfate in Male CD-1 Mice From a 3-Month Oral Gavage Toxicity Study. Toxicologic pathology. 2021 Jul;49(5):1100-1108

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33942680

    View Full Text